Microbiome and metabolome dynamics during radiotherapy for prostate cancer
Copyright © 2023 Elsevier B.V. All rights reserved..
BACKGROUND: Prostate cancer patients treated with radiotherapy are susceptible to acute gastrointestinal (GI) toxicity due to substantial overlap of the intestines with the radiation volume. Due to their intimate relationship with GI toxicity, faecal microbiome and metabolome dynamics during radiotherapy were investigated.
MATERIAL & METHODS: This prospective study included 50 prostate cancer patients treated with prostate (bed) only radiotherapy (PBRT) (n = 28) or whole pelvis radiotherapy (WPRT) (n = 22) (NCT04638049). Longitudinal sampling was performed prior to radiotherapy, after 10 fractions, near the end of radiotherapy and at follow-up. Patient symptoms were dichotomized into a single toxicity score. Microbiome and metabolome fingerprints were analyzed by 16S rRNA gene sequencing and ultra-high-performance liquid chromatography hybrid high-resolution mass spectrometry, respectively.
RESULTS: The individual α-diversity did not significantly change over time. Microbiota composition (β-diversity) changed significantly over treatment (PERMANOVA p-value = 0.03), but there was no significant difference in stability when comparing PBRT versus WPRT. Levels of various metabolites were significantly altered during radiotherapy. Baseline α-diversity was not associated with any toxicity outcome. Based on the metabolic fingerprint, no natural clustering according to toxicity profile could be achieved.
CONCLUSIONS: Radiation dose and treatment volume demonstrated limited effects on microbiome and metabolome fingerprints. In addition, no distinctive signature for toxicity status could be established. There is an ongoing need for toxicity risk stratification tools for diagnostic and therapeutic purposes, but the current evidence implies that the translation of metabolic and microbial biomarkers into routine clinical practice remains challenging.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:189 |
|---|---|
| Enthalten in: |
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology - 189(2023) vom: 11. Dez., Seite 109950 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Danckaert, Willeke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 28.11.2023 Date Revised 04.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.radonc.2023.109950 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363202900 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363202900 | ||
| 003 | DE-627 | ||
| 005 | 20231226092837.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.radonc.2023.109950 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1210.xml |
| 035 | |a (DE-627)NLM363202900 | ||
| 035 | |a (NLM)37827280 | ||
| 035 | |a (PII)S0167-8140(23)89844-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Danckaert, Willeke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Microbiome and metabolome dynamics during radiotherapy for prostate cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.11.2023 | ||
| 500 | |a Date Revised 04.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Prostate cancer patients treated with radiotherapy are susceptible to acute gastrointestinal (GI) toxicity due to substantial overlap of the intestines with the radiation volume. Due to their intimate relationship with GI toxicity, faecal microbiome and metabolome dynamics during radiotherapy were investigated | ||
| 520 | |a MATERIAL & METHODS: This prospective study included 50 prostate cancer patients treated with prostate (bed) only radiotherapy (PBRT) (n = 28) or whole pelvis radiotherapy (WPRT) (n = 22) (NCT04638049). Longitudinal sampling was performed prior to radiotherapy, after 10 fractions, near the end of radiotherapy and at follow-up. Patient symptoms were dichotomized into a single toxicity score. Microbiome and metabolome fingerprints were analyzed by 16S rRNA gene sequencing and ultra-high-performance liquid chromatography hybrid high-resolution mass spectrometry, respectively | ||
| 520 | |a RESULTS: The individual α-diversity did not significantly change over time. Microbiota composition (β-diversity) changed significantly over treatment (PERMANOVA p-value = 0.03), but there was no significant difference in stability when comparing PBRT versus WPRT. Levels of various metabolites were significantly altered during radiotherapy. Baseline α-diversity was not associated with any toxicity outcome. Based on the metabolic fingerprint, no natural clustering according to toxicity profile could be achieved | ||
| 520 | |a CONCLUSIONS: Radiation dose and treatment volume demonstrated limited effects on microbiome and metabolome fingerprints. In addition, no distinctive signature for toxicity status could be established. There is an ongoing need for toxicity risk stratification tools for diagnostic and therapeutic purposes, but the current evidence implies that the translation of metabolic and microbial biomarkers into routine clinical practice remains challenging | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Metabolome | |
| 650 | 4 | |a Microbiota | |
| 650 | 4 | |a Prospective studies | |
| 650 | 4 | |a Prostatic Neoplasms | |
| 650 | 4 | |a Radiotherapy | |
| 650 | 7 | |a RNA, Ribosomal, 16S |2 NLM | |
| 700 | 1 | |a Spaas, Mathieu |e verfasserin |4 aut | |
| 700 | 1 | |a Sundahl, Nora |e verfasserin |4 aut | |
| 700 | 1 | |a De Bruycker, Aurélie |e verfasserin |4 aut | |
| 700 | 1 | |a Fonteyne, Valérie |e verfasserin |4 aut | |
| 700 | 1 | |a De Paepe, Ellen |e verfasserin |4 aut | |
| 700 | 1 | |a De Wagter, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Vanhaecke, Lynn |e verfasserin |4 aut | |
| 700 | 1 | |a Ost, Piet |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology |d 1993 |g 189(2023) vom: 11. Dez., Seite 109950 |w (DE-627)NLM012598305 |x 1879-0887 |7 nnns |
| 773 | 1 | 8 | |g volume:189 |g year:2023 |g day:11 |g month:12 |g pages:109950 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.radonc.2023.109950 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 189 |j 2023 |b 11 |c 12 |h 109950 | ||